- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04297800
Gait Characteristics and Cognitive Evolution in Parkinson Disease (GECO-PD)
Gait Characteristics and Cognitive Evolution in Parkinson Disease (GECO-PARKINSON STUDY)
Parkinson's disease (PD) is a chronic progressive nervous system disease with gradual motor impairment. Cognitive dysfunction is common in PD, even in the early stages, and it is characterized by impairments in executive, attention, memory, language and visuospatial function. Motor symptoms, in particular, alterations in gait, have been studied in clinical practice to assess disease progression, and its response to treatments, both farmacological and physiotherapeutic.
Recent research on wearable technology in PD has shown that motor tests can be automated using wearable technology to eliminate human supervision and patient-reported data. Particularly, the quantitative gait analysis by using inertial devices has been proposed as a sensitive tool to longitudinally monitor gait worsening, response to dopaminergic treatment over time and cognitive dysfunction in PD patients.
The aim of this prospective multicente observational study is to investigate whether the dysfunction of specific gait parameters may be correlated to cognitive impairment (Attention/Executive Function Domain) in a cohort of ambulatory PD patients followed for 3 years.
Study Overview
Status
Conditions
Detailed Description
This is a prospective multicenter observational study with annual follow-up assessments over 3 years.
Gait is assessed by an inertial device (BTS G-WALK). G- WALK is an easy-to-use solution to obtain accurate, objective and quantitative spatial-temporal gait data. The device is a wireless system consisting of an inertial sensor composed by a triaxial accelerometer, a magnetic sensor, and a triaxial gyroscope that positioned on lumbar/ or sacral segments allows a functional gait analysis.
Cognitive performance is evaluated with a neuropsychological battery designed to assess memory, executive /attention, and visuospatial domains.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Dario Alimonti, MD, PhD
- Phone Number: +39 035-2673367
- Email: dalimonti@asst-pg23.it
Study Contact Backup
- Name: Rosalia Zangari, PhD
- Phone Number: +39 0352675134
- Email: rzangari@fondazionefrom.it
Study Locations
-
-
-
Bergamo, Italy, 24127
- ASST- Papa Giovanni XXIII
-
Brescia, Italy, 25123
- Spedali Civili di Brescia
-
Monza, Italy, 20900
- Ospedale San Gerardo di Monza
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Both sex
- Aged between 55-74 years
- Diagnosis of idiopathic PD based on MDS clinical diagnostic criteria
- Hoehn & Yahr (H&Y) stages 2 to 3 at enrollment, independently by PD duration
- Clinical-pharmacological stabilization until 3 months before the enrollment
- DBS treatment (stable stimulation parameters until 6 months before the enrollment)
Exclusion Criteria:
- Evidence of neurodegenerative and secondary parkinsonism
- Dementia ( (score <25 on the Mini Mental State Examination - MMSE)
- Psychiatric disorder (Beck Depression Inventory-II - BDI-II Score >19)
- Presence of organ failure (Modified Cumulative Illness Rating Scale - CIRS > 2)
- Orthopedic disorder or co-morbidities that may affect gait
- Drug and alcohol use
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Gait assessed by 6-Minute Walk Test (6MWT)
Time Frame: Every 6 months for 3 years
|
Gait assessment
|
Every 6 months for 3 years
|
Changes in Gait assessed by Extended-Time Up and Go (eTUG)
Time Frame: Every 6 months for 3 years
|
Gait assessment
|
Every 6 months for 3 years
|
Changes in cognitive function assessed by Mini-Mental State Examination (MMSE)
Time Frame: Every 6 months for 3 years
|
Cognitive Assessment.
The MMSE score ranges from 0 to 30 points, in which a lower score indicates a higher degree of cognitive impairment.
|
Every 6 months for 3 years
|
Changes in cognitive function assessed by the Montreal Cognitive Assessment (MoCA)
Time Frame: Every 6 months for 3 years
|
Cognitive Assessment.
The total score of the MoCA is 30 points, with a score less than 24 is considered cognitive impairment.
|
Every 6 months for 3 years
|
Changes in cognitive function assessed by Frontal Assessment Battery (FAB)
Time Frame: Every 6 months for 3 years
|
Cognitive Assessment
|
Every 6 months for 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Movement Disorder Society-Unified Parkinson's Disease Rating Scale, part III
Time Frame: Every 6 months for 3 years
|
The MDS-UPDRS III is the sum of 33 scores that evaluate Parkinson's disease motor symptoms on a scale from 0 to 4 points.
The total scale range is 0-132, where higher scores indicate more severe symptoms.
|
Every 6 months for 3 years
|
"Rapid eye movement Sleep" Behavior Disorder Screening Questionnaire
Time Frame: Every 6 months for 3 years
|
The RBDSQ ranges from 0 to 13, where higher scores represent a worse outcome.
|
Every 6 months for 3 years
|
Hyposmia Rating Scale
Time Frame: Every 6 months for 3 years
|
The scale ranges from 6 to 24, where higer scores indicate more worse sense of olfaction.
|
Every 6 months for 3 years
|
Beck Depression Inventory II
Time Frame: Every 6 months for 3 years
|
The BDI-II ranges from 0 to 63, where higer scores indicate more severe depressive symptoms.
|
Every 6 months for 3 years
|
Beck Anxiety Index
Time Frame: Every 6 months for 3 years
|
The BAI range is 0- 63, where higer scores indicate more severe symptoms.
|
Every 6 months for 3 years
|
Parkinson's Disease Questionnaire
Time Frame: Every 6 months for 3 years
|
PDQ-8 ranges from 0 to 32, where higher scores reflect a lower health-related quality of life.
|
Every 6 months for 3 years
|
Tinetti test
Time Frame: Every 6 months for 3 years
|
The test grants a maximum of 16 points for static part (sitting) and 12 point for dynamic (walking) part.
Higher is the score, better is the performance
|
Every 6 months for 3 years
|
Berg Balance Scale
Time Frame: Every 6 months for 3 years
|
The BBC includes 14 functional balance.
The scale ranges from 0 to 56, where higer scores indicate that the participant can complete the tasks.
|
Every 6 months for 3 years
|
short Falls Efficacy Scale
Time Frame: Every 6 months for 3 years
|
s-FES ranges from 7 to 28, where higher scores indicate high level of concern about falling during social and physical activities inside and outside the home.
|
Every 6 months for 3 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Dario Alimonti, MD, PhD, ASST- Papa Giovanni XXIII
- Study Chair: Francesco Biroli, MD, Fondazione per la Ricerca Ospedale di Bergamo (FROM)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GECO-PARKINSON STUDY
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia
-
BlueRock TherapeuticsMemorial Sloan Kettering Cancer CenterActive, not recruitingAdvanced Parkinson's DiseaseUnited States, Canada